389650 — NextBioMedical Co Income Statement
0.000.00%
Last trade - 00:00- KR₩700bn
- KR₩681bn
- KR₩10bn
Annual income statement for NextBioMedical Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.
2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | Annual Audited Accounts |
| Standards: | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final |
| Revenue | |||
| Total Revenue | 2,795 | 4,882 | 9,543 |
| Cost of Revenue | |||
| Gross Profit | 284 | 2,109 | 5,822 |
| Selling / General / Administrative Expenses | |||
| Research And Development | |||
| Depreciation and Amortization | |||
| Unusual Expense / Income | |||
| Total Operating Expenses | 7,657 | 12,534 | 8,027 |
| Operating Profit | -4,862 | -7,652 | 1,516 |
| Gain / Loss on Sale of Assets | |||
| Total Net Non Operating Interest Income / Expense | |||
| Other Net Non Operating Costs | |||
| Net Income Before Taxes | -5,732 | -7,522 | 2,860 |
| Provision for Income Taxes | |||
| Net Income After Taxes | -5,732 | -7,522 | 2,860 |
| Net Income Before Extraordinary Items | |||
| Net Income | -5,732 | -7,522 | 2,860 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||
| Income Available to Common Shareholders Including Extraordinary Items | |||
| Diluted Net Income | -5,732 | -7,522 | 2,860 |
| Diluted Weighted Average Shares | |||
| Basic EPS Including Extraordinary Items | |||
| Diluted EPS Including Extraordinary Items | |||
| Diluted EPS Excluding Extraordinary Items | |||
| Normalised Income Before Taxes | |||
| Normalised Income After Taxes | |||
| Normalised Income Available to Common Shareholders | |||
| Diluted Normalised EPS | -830 | -636 | -276 |
| Dividends per Share |